Characteristic,Expense in million U.S. dollars
Stock-based compensation,56.2
Shared discovery and development expenses,117.8
Technical development and unallocated manufacturing expenses,279.5
Platform research,93.5
Discovery programs,55.6
Systemic intracellular therapeutics*,21.0
Systemic secreted and cell surface therapeutics*,1.5
Localized regenerative therapeutics*,0.0
Intratumoral immuno-oncology*,8.8
Cancer vaccines*,29.4
Prophylactic vaccines*,707.2
